Clinical Efficacy, Antibiotic Resistance Genes, Virulence Factors and Outcome of Hospital-Acquired Pneumonia Induced by Klebsiella pneumoniae Carbapenemase 2-Producing with Tigecycline Treatment in the ICU
Xiang-Rong Bai,Jing-Rong Cao,Zhi-Zhou Wang,Wen-Chao Li,Dian-Dian Chen,Ran Lou,Xin Qu,Su-Ying Yan
DOI: https://doi.org/10.2147/IDR.S381280
2022-09-22
Infection and Drug Resistance
Abstract:Xiang-Rong Bai, 1, &ast Jing-Rong Cao, 2, &ast Zhi-Zhou Wang, 1 Wen-Chao Li, 1 Dian-Dian Chen, 2 Ran Lou, 3 Xin Qu, 4 Su-Ying Yan 1 1 Department of Pharmacy, Xuan Wu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People's Republic of China; 2 Department of Clinical Laboratory, Xuan Wu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People's Republic of China; 3 Department of Intensive Medicine, Xuan Wu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People's Republic of China; 4 Intensive Care Unit, Department of Neurosurgery, Xuan Wu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People's Republic of China &astThese authors contributed equally to this work Correspondence: Su-Ying Yan, Department of Pharmacy, Xuan Wu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, No. 45 Changchun Street, Xi Cheng District, Beijing, 100053, People's Republic of China, Tel/Fax +86 10-63012837, Email Purpose: Tigecycline is an agent for carbapenemase-producing Klebsiella pneumonia (KPC-KP), given its penetration into lung tissues. Our study focused on the molecular and clinical efficacy of tigecycline for hospital-acquired pneumonia (HAP) in the ICU. Patients and Methods: A retrospective cohort study of 52 adult KPC-KP HAP patients by searching hospital medical records from January 2018 to December 2020 was established to investigate the epidemiology of KPC-KP infections for tigecycline treatment and the associated clinical efficacy of tigecycline. The KPC-KP isolates underwent multilocus sequence typing. Molecular typing, antimicrobial resistance, and virulence profiling were also analyzed by whole-genome sequencing of KPC-KP. Results: Among 52 patients with KPC-KP, the ICU mortality rate was 14/52 (27%), and there was no significant statistical difference in mortality between the effective group and failure group ( p = 0.754). However, the duration of tigecycline was statistically different between the two groups of patients (14.4 vs 10 days, p =0.046). The total bacterial clearance rate was 6/52 (11.5%). There was no significant statistical difference in both groups ( p =0.416). Antibiotic resistance genes ( aac3iia ) and virulence gene ( AREO-iutA, Capsule-wzc ) were negatively correlated with clinical efficacy ( p = 0.011, OR = 1.237). Conclusions: Bla kpc was the main carbapenemase in all K. pneumoniae strains. ST11-KL64 KPC-KP was the most common virulence factors in KPC-KP isolates. This study suggested that antibiotic resistance genes ( aac3iia ) and virulence gene ( AREO-iutA, Capsule-wzc ) were independent mortality risk factors for patients with Klebsiella pneumoniae carbapenemase-2 producing K. pneumoniae infections, when during the tigecycline treatment. Molecular analysis of K. pneumoniae may provide an option when choosing the antimicrobial treatment. Keywords: Klebsiella pneumoniae , carbapenemase, virulence factors, resistance genes, hospital-acquired pneumonia Klebsiella pneumoniae is the most clinically relevant Klebsiella species, often exhibiting multidrug resistance and high virulence. Globally, K. pneumoniae infections are leading healthcare-associated infection. 1 The most common are pneumonia, urinary tract and abdominal infections, any of which can progress to bacteremia. In the last 10 years, carbapenem-resistant K. pneumoniae (CR-Kp) had increased from 3% in 2005 to 25.3% in 2019 in China. 2 The management of nosocomial infections due to CR-Kp infections has become challenging. The mortality rates of CR-Kp were between 23% and 75%, which are attributed to inappropriate empirical therapy and underlying comorbidities of patients. 3 A cohort study in ICU suggested that empirical antibiotic therapy, the use of piperacillin-tazobactam, was associated with mortality, and CR-Kp increased 20% of adjusted mortality. 4 The most mechanism of carbapenem resistance was carbapenem production in Klebsiella pneumoniae , particularly KPC in China. 5 Based on understanding of carbapenem resistance mechanisms can guide the selection of treatment option for CR-Kp. 6,7 The clinical evidence seems to indicate tigecycline has promising for KPC- Klebsiella pneumoniae -Abstract Truncated-
pharmacology & pharmacy,infectious diseases